Aidea Pharma(SH:688488) Zheng Quan Zhi Xing·2025-08-25 16:30Core Points - The company has completed the registration of the stock option incentive plan for 2025, with a total of 8.96 million stock options granted to 43 individuals [1][2][9] - The stock options will be issued through a targeted issuance of A-shares to the incentive recipients [1][2] - The incentive plan has undergone necessary decision-making procedures and has been approved by the board and supervisory committee [1][2] Summary by Sections Incentive Plan Details - The stock options granted will have a maximum validity period of 48 months from the date of the first grant [2][3] - The waiting periods for the stock options are set at 12 months and 24 months for different tranches [3][8] - The first tranche allows for 50% of the options to be exercised after 12 months, and the second tranche allows for 50% after 24 months [3][8] Performance Assessment - The performance assessment for the incentive plan will be conducted over two fiscal years, 2025 and 2026, with specific profit targets set for each year [6][7] - For non-marketing personnel, the net profit target for 2026 is set at 0.75 billion [7] - For marketing personnel, the revenue target for 2025 is set at 0.4 billion, with a trigger value of 0.32 billion [7][8] Financial Impact - The total estimated expense for the stock options granted is 35.32 million, which will be amortized over the years 2025, 2026, and 2027 [9][10] - The actual accounting costs may vary based on the performance of the incentive recipients and the company's financial results [9][10] - The plan is expected to enhance employee motivation and operational efficiency, potentially leading to improved company performance that outweighs the associated costs [10]